Asset
Taniraleucel
Celularity Inc. Class A Common Stock
Revenue
No revenue reported in loaded filings.
Clinical trials (2)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT02781467 | phase1 | terminated | 2016-07-11 | 2017-12-07 | Celularity Incorporated | A Safety Study of Human Cord Blood Derived, Culture Expanded Natural Killer Cell (PNK-007) Infusion With Subcutaneous Recombinant Human IL-2 (rhIL-2) in Adults With Relapsed and/or Refractory Acute Myeloid Leukemia (AML) |
| NCT02955550 | phase1 | completed | 2017-01-05 | 2018-07-10 | Celularity Incorporated | A Safety Study of Human Cord Blood Derived, Culture-expanded, Natural Killer Cell (PNK-007) Infusion With or Without Subcutaneous Recombinant Human Interleukin-2 (rhIL-2) Following Autologous Stem Cell Transplant for Multiple Myeloma (MM) |
FDA applications (0)
This company has no applications containing this asset.